PLX Protalix BioTherapeutics Inc

Price (delayed)

$1.47

Market cap

$66.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.38

Enterprise value

$107.96M

Highlights
Protalix BioTherapeutics's equity has surged by 154% QoQ and by 147% YoY
PLX's debt is down by 5% from the previous quarter
Protalix BioTherapeutics's quick ratio has surged by 98% QoQ but it has decreased by 3.1% YoY
PLX's EPS has dropped by 73% since the previous quarter but it is up by 41% year-on-year
PLX's net income has dropped by 109% since the previous quarter and by 46% year-on-year
The gross profit has declined by 25% year-on-year and by 22% since the previous quarter

Key stats

What are the main financial stats of PLX
Market
Shares outstanding
45.38M
Market cap
$66.71M
Enterprise value
$107.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.6
Price to sales (P/S)
1.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
Earnings
Revenue
$52.57M
EBIT
-$5.64M
EBITDA
-$4.43M
Free cash flow
-$29.75M
Per share
EPS
-$0.38
Free cash flow per share
-$0.74
Book value per share
$0.32
Revenue per share
$1.32
TBVPS
$2.57
Balance sheet
Total assets
$102.79M
Total liabilities
$88.29M
Debt
$61.08M
Equity
$14.5M
Working capital
$9.84M
Liquidity
Debt to equity
4.21
Current ratio
1.12
Quick ratio
0.93
Net debt/EBITDA
-9.32
Margins
EBITDA margin
-8.4%
Gross margin
76.8%
Net margin
-26%
Operating margin
-10.8%
Efficiency
Return on assets
-17.4%
Return on equity
N/A
Return on invested capital
-8.8%
Return on capital employed
-25.7%
Return on sales
-10.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-3.29%
1 week
-5.77%
1 month
-18.33%
1 year
-60.05%
YTD
-59.5%
QTD
-23.04%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$52.57M
Gross profit
$40.36M
Operating income
-$5.69M
Net income
-$13.67M
Gross margin
76.8%
Net margin
-26%
PLX's net margin has plunged by 150% from the previous quarter and by 83% YoY
PLX's net income has dropped by 109% since the previous quarter and by 46% year-on-year
The gross profit has declined by 25% year-on-year and by 22% since the previous quarter
Protalix BioTherapeutics's revenue has decreased by 20% YoY and by 16% from the previous quarter

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
N/A
P/B
4.6
P/S
1.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.05
PLX's EPS has dropped by 73% since the previous quarter but it is up by 41% year-on-year
Protalix BioTherapeutics's equity has surged by 154% QoQ and by 147% YoY
PLX's price to sales (P/S) is 68% lower than its 5-year quarterly average of 3.6 and 50% lower than its last 4 quarters average of 2.3
Protalix BioTherapeutics's revenue has decreased by 20% YoY and by 16% from the previous quarter

Efficiency

How efficient is Protalix BioTherapeutics business performance
The ROA has plunged by 98% from the previous quarter and by 10% YoY

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 16% greater than its total liabilities
Protalix BioTherapeutics's quick ratio has surged by 98% QoQ but it has decreased by 3.1% YoY
The company's current ratio has surged by 75% QoQ but it fell by 7% YoY
Protalix BioTherapeutics's equity has surged by 154% QoQ and by 147% YoY
PLX's debt is down by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.